Beginning Nov. 1, 2025, Novartis will launch a direct-to-patient (DTP) platform in the United States that offers cash-paying patients prescribed Cosentyx (secukinumab) the option to purchase it at a 55% discount off the list price.

Cosentyx is a biologic that is FDA-approved to treat multiple immune-mediated inflammatory diseases, including psoriasis, hidradenitis suppurativa, and psoriatic arthritis.Its list price as of July 2025 is $7,936.48 a month for either a 150-mg or a 300-mg dose strength self-injection package and $4,401.32 per intravenous infusion.

The price offered to cash-paying patients represents average savings that insurers and pharmacy benefit managers receive. The Cosentyx DTP platform serves as proof-of-concept for a direct-selling model for specialty medicines and i

See Full Page